The pharmaceutical companies Crescent Biopharma (US-based) and Kelun-Biotech (China-based) have announced a strategic partnership to exchange licensing rights for two... Read more
Tag: #Global Trends
Trial Data Opens Door for Earlier Use of Lilly’s BTK Inhibitor
(ORLANDO) – At an American Society of Hematology (ASH) meeting, the pharmaceutical company Eli Lillypresented results from a critical head-to-head... Read more
AstraZeneca Expands Amyloidosis Collaboration with Deal Potentially Reaching $780 Million
Alexion Pharmaceuticals, the rare disease unit of AstraZeneca, has expanded its partnership with biotech company Neurimmune by licensing a second... Read more
Major Funding Deal: Therapeutics Company Secures $275 Million Through Drug Royalty Agreement
A therapeutics company has announced a funding agreement worth $275 million with a financial fund specializing in pharmaceutical royalties. The... Read more
A New Breakthrough in Duchenne Muscular Dystrophy Treatment: Promising Phase 3 Trial Results
A therapeutics company has announced positive topline results from its pivotal Phase 3 HOPE-3 clinical trial, evaluating the efficacy of... Read more
European Authorities Clear Novel Autoimmune Therapy for Myasthenia Gravis
The European Commission has granted authorization for nipocalimab, an immunoglobulin G (IgG) receptor antagonist developed by Johnson & Johnson, for... Read more
Vetter Managing Director to Retire Following Over Three Decades of Service
Vetter, a globally leading Contract Development and Manufacturing Organization (CDMO), has announced the retirement of its Managing Director, Thomas Otto,... Read more
New Study Suggests Shingles Vaccine May Slow Cognitive Decline
A new follow-up study, published in the journal Cell, adds evidence that the shingles vaccine, a two-dose shot recommended for... Read more
Bristol Myers Bolsters Scale of Cobenfy Trial After Discovery of Site Irregularities
Bristol Myers Squibb (BMS) has announced an extension and increased enrollment for its late-stage clinical trial, “ADEPT-2,” of the drug... Read more









